At least, combining analogs of somatostatin and blockade of the DLK1/MEG3 locus could be an effective treatment strategy for somatotroph adenomas, especially for patients with overactivation of the DLK1/MEG3 locus and resistance to standard treatment. This evidence concerns the gene DLK1 and familial isolated pituitary adenoma.